Immatics abstract accepted for late-breaking poster presentation at AACR meeting

Immatics (IMTX) announced that an abstract highlighting a pediatric patient treated with a PRAME-directed cell therapy using Immatics’ PRAME T-cell receptor has been accepted for a late-breaking poster presentation at the American Association for Cancer Research Annual Meeting 2026 in San Diego, California. The patient case will be presented on April 21, at 2:00 pm PDT, by the treating physician, the company stated. Cedrik Britten, M.D., Ph.D., Chief Medical Officer at Immatics, said, “Seeing such a profound response in a pediatric patient who had no treatment options left is both remarkable and deeply encouraging for everyone dedicated to making a meaningful impact on the lives of patients with cancer. It reinforces our belief in PRAME as a powerful target and highlights the potential of cell therapy for pediatric cancers, where tumors often show high PRAME expression. These results support continued evaluation of PRAME-directed cell therapies in pediatric cancers while exploring new therapeutic options for children facing such devastating diseases.”